PubRank

Manuela Campiglio

Author PubWeight™ 49.82‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005 27.56
2 Role of HER2 in wound-induced breast carcinoma proliferation. Lancet 2003 3.40
3 Biologic and therapeutic role of HER2 in cancer. Oncogene 2003 2.26
4 Apoptosis induction by trastuzumab: possible role of the core biopsy intervention. J Clin Oncol 2005 1.49
5 Molecular markers to predict response to gefitinib: EGFR, ErbB-2, or more? J Clin Oncol 2004 1.46
6 Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. J Cell Physiol 2012 1.45
7 The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol 2006 1.37
8 HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. Clin Cancer Res 2002 1.00
9 HER2 as a target for breast cancer therapy. Expert Opin Biol Ther 2010 0.99
10 FHIT-proteasome degradation caused by mitogenic stimulation of the EGF receptor family in cancer cells. Proc Natl Acad Sci U S A 2006 0.95
11 Activity and resistance of trastuzumab according to different clinical settings. Cancer Treat Rev 2011 0.90
12 Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling. Breast Cancer Res Treat 2007 0.89
13 Protein kinase Calpha determines HER2 fate in breast carcinoma cells with HER2 protein overexpression without gene amplification. Cancer Res 2007 0.88
14 Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility. J Cell Physiol 2010 0.87
15 Tyrosine phosphorylation of Grb2: role in prolactin/epidermal growth factor cross talk in mammary epithelial cell growth and differentiation. Mol Cell Biol 2009 0.85
16 Re: Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst 2004 0.83
17 Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN. J Immunother 2010 0.82
18 Fhit expression protects against HER2-driven breast tumor development: unraveling the molecular interconnections. Cell Cycle 2007 0.82
19 The adaptor function of SHP-2 downstream of the prolactin receptor is required for the recruitment of p29, a substrate of SHP-2. Cell Signal 2003 0.79
20 The HER2 World: Better Treatment Selection for Better Outcome. J Natl Cancer Inst Monogr 2011 0.76
21 PET prediction of response to trastuzumab in ErbB2-positive human xenograft model. J Nucl Med 2012 0.75